Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
20 Julho 2023 - 9:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it will report financial
results for the second quarter ending June 30, 2023 on Thursday,
August 3, 2023, before the U.S. financial markets open.
Management will provide an update on the Company and discuss
second quarter 2023 results as well as expectations for the future
via conference call on Thursday, August 3, 2023 at 8:30 am ET. To
access the call, please register online at
https://register.vevent.com/register/BI8e6d8bfa374f41278e284759aa762e9e.
Participants are requested to register a day in advance or at a
minimum 15 minutes before the start of the call. A replay of the
call will be available two hours after the call and archived on the
same web page for six months.
A live audio webcast of the call will be available on the
Investors section of the Company’s website at
www.alnylam.com/events. An archived webcast will be available on
the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation
of RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and prevalent diseases with unmet need. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach yielding transformative
medicines. Since its founding 20 years ago, Alnylam has led the
RNAi Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), AMVUTTRA®
(vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and
Leqvio® (inclisiran), which is being developed and commercialized
by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam, on LinkedIn, or on
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230720442183/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340 Josh Brodsky (Investors)
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024